Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies

BACKGROUND: Cervical cancer is now considered the second leading cause of death among women worldwide, and its incidence has reached alarming levels, especially in developing countries. Similarly, high grade squamous intraepithelial lesion (HSIL), the precursor stage for cervical cancer, represents...

Descripción completa

Detalles Bibliográficos
Autores principales: Solares, Ana M, Santana, Agueda, Baladrón, Idania, Valenzuela, Carmen, González, Carlos A, Díaz, Alina, Castillo, Dagnelia, Ramos, Thelvia, Gómez, Roberto, Alonso, Daniel F, Herrera, Luis, Sigman, Hugo, Perea, Silvio E, Acevedo, Boris E, López-Saura, Pedro
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689241/
https://www.ncbi.nlm.nih.gov/pubmed/19439079
http://dx.doi.org/10.1186/1471-2407-9-146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2689241/
https://www.ncbi.nlm.nih.gov/pubmed/19439079
http://dx.doi.org/10.1186/1471-2407-9-146

Ejemplares similares